On 27 September 2018, dacomitinib (Figure 21) was approved by the FDA for use in the treatment of metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations [63]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.